INS and cystic fibrosis-related diabetes: Previous pharmacological attempts beyond insulin, such as GLP-1 receptor agonists, have shown potential to improve glucose tolerance and postprandial insulin secretion in CFRD but have been limited by gastrointestinal side effects and modest efficacy [11].